Xvivo Perfusion AB (XVIVO) AI Stock Analysis

• Market Cap: $6.13B
• Dividend Yield: N/A
• Average Volume (3M): 193.81K
• Price to Earnings (P/E): 54.0
• Beta (1Y): 1.35
• Revenue Growth: 17.78%
• EPS Growth: -7.83%
• Country: SE
• Employees: 193
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): 0.05
• Shares Outstanding: 31,499,470
• 10 Day Avg. Volume: 190,952
• 30 Day Avg. Volume: 193,805
• PEG Ratio: 1.14
• Price to Book (P/B): 7.14
• Price to Sales (P/S): 18.73
• P/FCF Ratio: -188.16
• Enterprise Value/Market Cap: 1.42
• Enterprise Value/Revenue: 10.59
• Enterprise Value/Gross Profit: 14.14
• Enterprise Value/Ebitda: 101.32
• 1Y Price Target: $324.01
• Price Target Upside: 71.62% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: kr212.00 ▲(12.29% Upside)

The overall stock score reflects strong financial performance, which is the most significant positive factor. However, the technical analysis indicates negative market momentum, and the high P/E ratio suggests potential overvaluation, both of which weigh down the overall score.

Xvivo Perfusion AB Business Overview & Revenue Model

Company Description

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

How the Company Makes Money

XVIVO generates revenue primarily through the sale of its organ preservation and perfusion solutions to hospitals and transplant centers globally. The company's product portfolio includes proprietary preservation solutions and advanced perfusion machines that enhance organ viability during transportation and before transplantation. Additionally, XVIVO earns income from consumable products required for each use of its perfusion systems, creating a recurring revenue stream. The company also engages in strategic partnerships with leading medical institutions and research organizations to further develop and expand its product offerings, thereby contributing to its revenue growth.

Xvivo Perfusion AB Financial Statement Overview

Summary

Xvivo Perfusion AB shows strong financial health with substantial revenue growth, efficient cost management, and a robust balance sheet with no debt. However, there is room for improvement in operational efficiencies and cash flow stability.

Income Statement

Xvivo Perfusion AB's income statement reveals robust growth and profitability. The revenue has shown a remarkable growth rate, increasing from 597,542,000 to 822,415,000 (37.6%) year-over-year. Gross Profit Margin is solid at 74.9%, indicating efficient cost management. The Net Profit Margin has increased to 20.9%, showcasing improved profitability. However, the EBIT and EBITDA margins need attention, as they are both at 10.7%, suggesting potential for operational efficiency improvements.

Balance Sheet

The balance sheet of Xvivo Perfusion AB is strong, with a high equity ratio of 89.8%, indicating financial stability. The company has no total debt, resulting in a favorable debt-to-equity ratio of 0. The Return on Equity (ROE) is impressive at 8.0%, reflecting effective use of shareholder funds. Overall, the balance sheet reflects a healthy, low-leverage financial position.

Cash Flow

Xvivo Perfusion AB demonstrates a positive cash flow position. Operating Cash Flow increased significantly to 111,290,000, highlighting operational efficiency. The Free Cash Flow to Net Income ratio is positive and indicates that the company is generating sufficient cash relative to its net income. However, the Free Cash Flow Growth Rate is not favorable due to prior negative free cash flows, posing a potential risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	822.93M	822.41M	597.54M	415.29M	258.39M	179.86M
Gross Profit	616.09M	616.41M	445.11M	296.96M	188.28M	132.97M
EBITDA	85.98M	272.97M	126.57M	39.21M	39.20M	-43.33M
Net Income	111.38M	172.18M	91.82M	18.43M	8.15M	-43.73M
Balance Sheet
Total Assets	2.39B	2.40B	2.20B	1.73B	1.54B	1.15B
Cash, Cash Equivalents and Short-Term Investments	323.00M	415.52M	546.09M	246.54M	398.70M	353.44M
Total Debt	110.81M	34.04M	31.44M	10.01M	5.72M	7.21M
Total Liabilities	295.46M	245.97M	250.57M	302.95M	257.15M	141.85M
Stockholders Equity	2.09B	2.16B	1.95B	1.43B	1.29B	1.01B
Cash Flow
Free Cash Flow	78.51M	-81.86M	-97.65M	-103.09M	-106.13M	-76.94M
Operating Cash Flow	78.51M	111.29M	46.29M	27.86M	-12.06M	-12.27M
Investing Cash Flow	-284.20M	-243.81M	-161.62M	-197.62M	-187.70M	-266.53M
Financing Cash Flow	73.55M	-10.90M	418.55M	-6.84M	234.61M	482.77M

Xvivo Perfusion AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 188.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XVIVO, the sentiment is Negative. The current price of 188.8 is below the 20-day moving average (MA) of 208.42, below the 50-day MA of 258.41, and below the 200-day MA of 372.23, indicating a bearish trend. The MACD of -19.50 indicates Negative momentum. The RSI at 28.46 is Positive, neither overbought nor oversold. The STOCH value of 3.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XVIVO.

Xvivo Perfusion AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XVIVO	64 Neutral	$6.13B	53.99	5.17%	―	17.78%	-7.83%
Sector *	51 Neutral	$7.38B	-0.04	-62.85%	2.34%	15.18%	-2.87%
0YAY	―	kr18.35B	40.42	3.46%	5.43%	―	―
ARRJF	―	$933.42M	22.62	5.34%	3.14%	―	―
BITGF	―	$1.21B	50.22	6.41%	0.08%	―	―
RSLBF	―	$1.08B	59.97	22.81%	0.96%	―	―
SUS	57 Neutral	kr5.12B	36.31		―	12.41%	-32.19%

Xvivo Perfusion AB Corporate Events

XVIVO Faces Delay in CE Approval for Heart Perfusion Solution

XVIVO Perfusion AB has announced a delay in the CE approval for its heart perfusion solution, part of its heart preservation technology, due to additional consultation required by EU authorities. Despite this setback, the company’s Heart Assist Transport system has received CE approval, and recent trial results show significant improvements in patient survival, highlighting the technology’s potential impact on heart transplantation.

The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

XVIVO Initiates US PRESERVE CAP Study for Heart Assist Device

XVIVO Perfusion AB has announced the enrollment of the first patient in the US PRESERVE CAP study for its XVIVO Heart Assist Transport device. This study, approved by the FDA, allows continued clinical use of the device while XVIVO prepares its Pre-Market Approval application. The study’s approval by the Centers for Medicare & Medicaid Services ensures cost recovery, supporting both participating centers and patients. This initiative underscores XVIVO’s commitment to providing life-saving technologies and maintaining continuity of care during the evaluation period.

The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

Xvivo Perfusion AB Faces Sales Decline Amid Strategic Investments in H1 2025

Xvivo Perfusion AB reported a challenging first half of 2025, with net sales declining by 15% in SEK and 9% in local currencies. The company’s thoracic and services segments experienced negative growth, while the abdominal segment showed a positive sales increase. Despite a stable gross margin, the company faced a significant drop in operating income and net profit, largely due to currency effects and strategic investments in R&D and inventory. These financial results reflect the company’s ongoing efforts to adapt to market conditions and invest in future growth, though they pose challenges for stakeholders in the short term.

The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

XVIVO Perfusion AB Schedules Conference Call for Q2 2025 Interim Report

XVIVO Perfusion AB announced a conference call to discuss their interim report for April-June 2025, scheduled for July 11, 2025. This event will provide stakeholders with insights into the company’s recent performance and strategic direction, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (SE:XVIVO) stock is a Buy with a SEK460.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

XVIVO Perfusion AB Wins 2025 SACC-USA Business Award for U.S. Market Growth

XVIVO Perfusion AB has been awarded the 2025 SACC-USA Business Award for its innovative contributions and growth in the U.S. market, particularly in organ perfusion and preservation technologies. This recognition underscores XVIVO’s significant impact on the U.S. healthcare system by addressing the growing demand for organ transplants and highlights the company’s role in strengthening Swedish-American business ties through its life-saving innovations.

The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.